Manufacturing gene and cell therapies is among the hardest challenges in all of biotech, and for most developers, choosing the right contract manufacturer is one of the most consequential decisions they will make. These therapies are complex, the specialized expertise is scarce, and quality manufacturing capacity is in high demand, so the stakes of choosing well, or badly, are enormous. The right gene and cell therapy CDMO is one with proven, specific expertise in your exact modality, genuine available capacity, a strong quality and regulatory track record, and the ability to transfer and scale your process reliably. Here is how to choose.
Understand why this is uniquely hard
Gene and cell therapy manufacturing differs fundamentally from traditional drug manufacturing. The processes are highly complex and often personalized, the science is still maturing, the required expertise and facilities are specialized and relatively scarce, and demand for quality capacity has frequently outstripped supply. On top of that, the regulatory expectations for these advanced therapies are demanding and evolving. All of this means you are not simply outsourcing production; you are entrusting a difficult, specialized process to a partner whose expertise and capacity will directly determine whether your therapy can be made reliably and to standard. Appreciating this difficulty is the starting point for choosing carefully.
What to look for
Evaluate CDMOs against the factors that matter most for advanced therapies.
- Specific modality expertise. Does the CDMO have proven, direct experience with your exact type of therapy, whether a particular kind of cell therapy, a specific viral vector, or another modality? General manufacturing experience is not enough; you need specific, demonstrated expertise in your modality.
- Genuine capacity and availability. Do they actually have the capacity available when you need it? Because quality capacity is constrained, confirming real availability on your timeline is critical.
- Quality and regulatory track record. Do they have a strong record of quality and compliance specifically in advanced therapies, an area regulators scrutinize closely?
- Technology transfer and scalability. Can they transfer your process cleanly and scale it as you advance, without losing quality or consistency?
- Analytical and process capabilities. Do they have the specialized analytical and process expertise these complex therapies require?
Questions to ask
Specific questions cut to what matters. Ask about their direct experience with your exact modality, and for concrete evidence. Ask candidly about capacity and timelines, and whether they can genuinely accommodate your program when you need it. Ask about their quality and regulatory track record in advanced therapies. Ask how they approach technology transfer and scale-up. And probe their analytical and process capabilities. Given the complexity and the scarcity of true expertise, the specificity and credibility of their answers, backed by real experience, are what separate a capable partner from a risky one.
Red flags to watch for
Be alert to warning signs. Be wary of CDMOs claiming broad capability without specific, proven experience in your exact modality, since advanced-therapy manufacturing does not generalize. Treat vague or overly optimistic answers about capacity and timelines with caution, since capacity constraints are real and overcommitment causes serious problems. Any weakness in the quality and regulatory track record for advanced therapies is a major concern. And be careful of CDMOs that underestimate the difficulty of technology transfer and scale-up for your therapy. Because a manufacturing failure in this field can set a program back severely, rigorous scrutiny is warranted.
How to find candidates
To find gene and cell therapy CDMOs worth evaluating, industry directories let you identify manufacturers by their specific advanced-therapy focus, so you can build a shortlist of those with genuinely relevant expertise. From there, evaluate rigorously for modality-specific experience, real capacity, quality track record, and technology-transfer capability, and choose the partner whose specialized expertise and availability best fit your program. Given how consequential and difficult this decision is, a thorough, criteria-driven selection process is essential rather than optional.
The bottom line
Choosing a gene and cell therapy CDMO well means recognizing how uniquely demanding advanced-therapy manufacturing is, then selecting for proven expertise in your specific modality, genuine available capacity, a strong quality and regulatory track record, and reliable technology transfer and scale-up. Watch for broad claims without specific experience, capacity overcommitment, quality weaknesses, and underestimation of transfer challenges. Use directories to find specialists, then scrutinize rigorously. The right CDMO can make your therapy a reality; the wrong one can jeopardize it, which is why this decision deserves exceptional care.
Start early and plan for a long relationship
A practical reality of gene and cell therapy manufacturing is that you should engage a CDMO earlier than you might for conventional products, because capacity is constrained and the processes are complex, and planning for a long, evolving relationship is essential. Given that quality capacity in advanced therapies has often been in short supply, securing a manufacturing partner well ahead of when you need production is prudent, since waiting until the last minute can leave you without access to a suitable partner on your timeline, potentially delaying your program. Engaging early also allows time for the substantial work of technology transfer and process development that these therapies require, which cannot be rushed without risking quality. It helps to think of the CDMO relationship as a long partnership rather than a transaction, because you will likely work together closely over an extended period as your therapy advances from early production through scale-up, and the quality of that ongoing collaboration matters enormously. Building in appropriate flexibility is wise too, since programs evolve, timelines shift, and needs change, so a relationship and agreement that can adapt serve you better than rigid arrangements that assume everything will go to plan. Clear communication and genuine collaboration throughout are especially important given the complexity and the evolving nature of the science, so choosing a partner you can work with closely and trust over time is as important as their technical capabilities. It also pays to plan for scale from the beginning, considering not just your immediate production needs but how the partnership will support you as your therapy advances toward larger-scale manufacturing, since a partner who can grow with you avoids the disruption of switching manufacturers later. Developers who engage a gene or cell therapy CDMO early, plan for a long and evolving partnership, build in flexibility, and prioritize a strong working relationship position themselves far better than those who treat manufacturing as a late-stage, transactional concern, which is fitting given how central and difficult manufacturing is for these advanced therapies.
The bottom line
Choosing a gene and cell therapy CDMO well means recognizing how uniquely demanding advanced-therapy manufacturing is, then selecting for proven expertise in your specific modality, genuine available capacity, a strong quality and regulatory track record, and reliable technology transfer and scale-up, while engaging early and planning for a long, evolving partnership. Watch for broad claims without specific experience, capacity overcommitment, quality weaknesses, and underestimation of transfer challenges, and use directories to find genuine specialists before scrutinizing rigorously. Because manufacturing is so central and difficult for advanced therapies, and a failure can set a program back severely, this decision deserves exceptional care and early attention. The right CDMO, chosen carefully and engaged as a true long-term partner, can make your therapy a reality; the wrong one can jeopardize everything you have built.
To find gene and cell therapy CDMOs and manufacturers, browse the BioMed Nexus gene and cell therapy directory. For related reading, see our overview of the cell and gene therapy CDMO landscape and our general guide on how to choose a CDMO.
Frequently asked questions
How do I choose a gene and cell therapy CDMO?
Recognize how uniquely demanding advanced-therapy manufacturing is, then evaluate CDMOs on proven, specific expertise in your exact modality, genuine available capacity on your timeline, a strong quality and regulatory track record in advanced therapies, and reliable technology transfer and scale-up. General manufacturing experience is not enough; you need demonstrated, modality-specific capability. Use directories to find specialists.
Why is gene and cell therapy manufacturing so difficult?
Because the processes are highly complex and often personalized, the science is still maturing, the required expertise and facilities are specialized and relatively scarce, quality capacity has often outstripped supply, and regulatory expectations are demanding and evolving. This means choosing a CDMO is entrusting a difficult, specialized process to a partner whose expertise and capacity directly determine whether the therapy can be made reliably.
What are red flags in a cell and gene therapy CDMO?
Be wary of CDMOs claiming broad capability without specific proven experience in your exact modality, vague or overly optimistic answers about capacity and timelines, any weakness in the quality and regulatory track record for advanced therapies, and underestimation of the difficulty of technology transfer and scale-up. A manufacturing failure in this field can set a program back severely, so scrutiny is essential.
